Format

Send to

Choose Destination
Leukemia. 2019 Apr;33(4):1011-1022. doi: 10.1038/s41375-018-0263-1. Epub 2018 Oct 12.

Inhibitors of the protein disulfide isomerase family for the treatment of multiple myeloma.

Author information

1
Department of Cell and Molecular Pharmacology & Experimental Therapeutics, College of Medicine, Medical University of South Carolina, Charleston, SC, USA.
2
Fox Chase Chemical Diversity Center, Inc., Doylestown, PA, USA.
3
Department of Drug Discovery and Biomedical Sciences, College of Pharmacy, Medical University of South Carolina, Charleston, SC, USA.
4
Department of Chemistry and Biochemistry, College of Science, University of Notre Dame, Notre Dame, IN, USA.
5
Department of Medicine, Mayo Clinic Arizona, Scottsdale, AZ, USA.
6
Department of Cell and Molecular Pharmacology & Experimental Therapeutics, College of Medicine, Medical University of South Carolina, Charleston, SC, USA. dolloffn@musc.edu.

Abstract

Multiple Myeloma (MM) is highly sensitive to disruptions in cellular protein homeostasis. Proteasome inhibitors (PIs) are initially effective in the treatment of MM, although cures are not achievable and the emergence of resistance limits the durability of responses. New therapies are needed for refractory patients, and those that combat resistance to standard of care agents would be particularly valuable. Screening of multiple chemical libraries for PI re-sensitizing compounds identified E61 as a potent enhancer of multiple PIs and MM specific activity. Using a tandem approach of click chemistry and peptide mass fingerprinting, we identified multiple protein disulfide isomerase (PDI) family members as the primary molecular targets of E61. PDIs mediate oxidative protein folding, and E61 treatment induced robust ER and oxidative stress responses as well as the accumulation of ubiquitinylated proteins. A chemical optimization program led to a new structural class of indene (exemplified by lead E64FC26), which are highly potent pan-style inhibitors of PDIs. In mice with MM, E64FC26 improved survival and enhanced the activity of bortezomib without any adverse effects. This work demonstrates the potential of E64FC26 as an early drug candidate and the strategy of targeting multiple PDI isoforms for the treatment of refractory MM and beyond.

PMID:
30315229
DOI:
10.1038/s41375-018-0263-1

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center